Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide/GLP-1 (GIP/GLP-1) receptor agonists are well-established in various clinical settings, including glucose control in type 2 diabetes and weight loss in people with and without diabetes [1,2]. This evidence concerns the gene GIP and type 2 diabetes mellitus.